Day: November 8, 2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

Written by Customer Service on November 8, 2024. Posted in Public Companies.

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers) Paris, France (November 8, 2024 – 6:00 pm) – As of October 31, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below. October 31, 2024Shares outstanding 457,322,5071Number of real voting rights (excluding treasury shares) 456,762,601Theoretical number of voting rights (including treasury shares) 457,322,507It is to be noted that voting rights are capped at 31%, applicable to any shareholder, in accordance with a formula contained in...

DFCU Financial Announces Intent to Acquire Winter Park National Bank, Expanding Florida Footprint

Written by Customer Service on November 8, 2024. Posted in Mergers And Acquisitions.

DEARBORN, Mich. and WINTER PARK, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) — DFCU Financial, one of Michigan’s largest and most trusted credit unions, is pleased to announce its intent to acquire Winter Park National Bank (WPNB), a well-established financial institution based in Winter Park, FL. This acquisition marks DFCU Financial’s third transaction within the state of Florida, furthering its commitment to providing comprehensive financial services and superior member experiences across the region. Winter Park National Bank, founded in 2017, serves the Winter Park-Orlando-Kissimmee area with a strong reputation for customer service and personalized banking solutions. The acquisition of WPNB will complement DFCU Financial’s existing presence in Florida, which already includes branches in Tampa, St. Petersburg, Naples, and Ft....

Euronext announces volumes for October 2024

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

Euronext announces volumes for October 2024 Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 8 November 2024 – Euronext today announced trading volumes for October 2024. Monthly and historical volume tables are available at this address: https://euronext.com/investor-relations#monthly-volumes CONTACTS ANALYSTS & INVESTORS – ir@euronext.com Investor Relations Aurélie Cohen +33 1 70 48 24 17 Judith Stein +33 6 15 23 91 97 MEDIA – mediateam@euronext.com Europe Aurélie Cohen +33 1 70 48 24 45 Andrea Monzani +39 02 72 42 62 13 Belgium Marianne Aalders +32 26 20 15 01 France, Corporate Flavio Bornancin-Tomasella +33 1 70 48 24 45 Ireland Andrea Monzani +39 02 72 42 62...

Pineapple Energy Shareholders Overwhelmingly Approve Incorporation to Delaware and New Corporate Name Change to SUNation Energy, Inc.

Written by Customer Service on November 8, 2024. Posted in Public Companies.

RONKONKOMA, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (Nasdaq: PEGY) (Pineapple Energy) (“Pineapple” or the “Company”), a leading provider of sustainable solar energy and backup power to households, businesses, municipalities, and for servicing existing systems, today announced that it is changing its corporate name to SUNation Energy, Inc. (“SUNation”). The effective date for the name change will be announced in the near term. The corporate name change and a proposal to approve the redomestication and change in the Company’s legal state of incorporation from Minnesota to Delaware were each overwhelmingly approved at a Special Meeting of Shareholders held on November 4, 2024. “The adoption of SUNation Energy, Inc. as our corporate name leverages the significant brand equity we have built over the last 20-plus...

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

Written by Customer Service on November 8, 2024. Posted in Public Companies.

8 November 2024 New Release BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences COPENHAGEN, DENMARK and BOSTON, MA, USA, November 8, 2024 – BioPorto Diagnostics, a pioneering company in the field of diagnostic biomarkers, today announced that the Company has sponsored exhibits at the following clinical healthcare conferences via invitation from conference organizers: 10th World Academic Congress of Emergency Medicine (WACEM 24), Rome, Italy (November 6th to 8th, 2024) 22nd Annual California Association of Neonatologists Annual Academic Day, Irvine, CA, (November 7, 2024) PICNIC: “Pediatric Intensive, Cardiac, and Neonatal Intensive Care Collaborative Conference”, New York, New York (November 8, 2024) Jennifer Zonderman...

United-Guardian Reports Increased Third Quarter Earnings

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

HAUPPAUGE, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) — United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2024. Sales for the nine-month period ended September 30th increased from $8,278,141 in 2023 to $9,705,262 in 2024 and net income increased from $1,843,931 ($0.40 per share) to $2,747,151 ($0.60 per share) for the same period. The third quarter remained steady with sales of $3,057,518 in 2023 and $3,060,113 in 2024, while net income increased from $626,756 ($0.14 per share) to $865,484 ($0.19 per share). Donna Vigilante, President of United-Guardian, stated, “We are pleased to announce that sales and earnings increased in the third quarter and for the first nine months of 2024 compared with the same periods in 2023. We continue to have strong sales of our cosmetic...

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells, GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025 Announced increased focus on type 1 diabetes and B-cell mediated autoimmune diseases  Cash position of $199.0 million with expected cash runway into 2026 SEATTLE, Nov. 08, 2024 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the third quarter 2024. “Early...

Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024

Written by Customer Service on November 8, 2024. Posted in Public Companies.

Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars highlighted Medigene’s proprietary End-to-End Platform for generation of extraordinary T cell receptors for application in various modalities and overview of the lead TCR-T therapy program MDG1015Planegg/Martinsried, November 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, highlighted recent advances in its proprietary End-to-End Platform to create optimal safe, sensitive, and specific (3S) T cell receptors that can be applied in various modalities, including therapies...

VEON Group Reaffirms Commitment to Strengthen Pakistan’s Digital Infrastructure in Meeting with Prime Minister

Written by Customer Service on November 8, 2024. Posted in Public Companies.

A VEON delegation led by Chairman and Founder Augie Fabela, Group CEO Kaan Terzioglu and Jazz CEO Aamir Ibrahim visited Prime Minister of Pakistan Shehbaz Sharif today in Islamabad.A VEON delegation led by Chairman and Founder Augie Fabela, Group CEO Kaan Terzioglu and Jazz CEO Aamir Ibrahim visited Prime Minister of Pakistan Shehbaz Sharif today in Islamabad. Islamabad, 8 November 2024 – VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator, is pleased to announce that a VEON delegation led by VEON Chairman and Founder Augie Fabela, VEON Group CEO Kaan Terzioglu and Jazz CEO Aamir Ibrahim visited Prime Minister of Pakistan Shehbaz Sharif today in Islamabad, to discuss the advancement of the country’s digital landscape. The Prime Minister commended Jazz’s role in driving digital transformation...

LITGRID AB publishes results for the 9 months of 2024

Written by Customer Service on November 8, 2024. Posted in Public Companies.

LITGRID AB, company code 302564383, registered office address Karlo Gustavo Emilio Manerheimo str. 8, Vilnius, Lithuania, is publishing results of the Company for the nine months of 2024. Key financial indicators for 9 months of 2024:Main financial results 9 months of 2024 9 months of 2023Revenue, EUR million 279.6 274.9EBITDA, EUR million 48.6 62.1Net profit, EUR million 31.7 43.3ROE (for the last 12 months), percents 16.3 19.5Adjusted* EBITDA, EUR million 37.3 29.6Adjusted* NET profit, EUR million 22.1 15.6Adjusted* ROE (for the last 12 months), percents 12.6 9.2*The adjustment of profitability ratios is made due to temporary regulatory deviations from the regulated profitability approved by the National Energy Regulatory Council (NERC). The calculation of the adjusted ratios shall take into account the adjustment...

Day: November 8, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice